国产基因测序龙头华大智造（688114）祭出大动作。近期，华大智造宣布，拟以3.66亿元分别受让实控 人汪建旗下两家公司深圳华大三箭齐发科技有限责任公司（以下简称"三箭齐发"）、杭州华大序风科技 有限公司（以下简称"华大序风"）的100%股权。这并非一次普通的资产腾挪，其核心在于将华大体系 内，代表生命科学研究两大前沿方向的时空组学与纳米孔测序技术平台正式纳入华大智造这一上市主体 的版图之中。在收购股权的同时，华大智造将分别对三箭齐发、华大序风增资7000万元、6000万元。此 外，华大智造还将向华大序风提供7000万元的3年期借款用于偿债。 此次交易因其涉及的前沿技术属性与战略协同潜力，受到市场与投资者的高度关注。然而，标的公司作 为华大智造实控人旗下资产，目前仍处于高投入研发阶段，尚未实现盈利，且此次交易标的公司评估增 值率较高。交易定价合理性、未来业绩实现路径等问题也值得投资者审慎关注。2月3日，华大智造相关 负责人就上述交易接受了北京商报记者采访。 "此次交易后，公司将彻底打通'短读长+长读长+时空组学'的一站式技术链条，使华大智造成为全球范 围内唯一同时覆盖这三大前沿技术的企业"，华大智造相关负责人 ...

国产基因测序龙头华大智造祭出大动作。华大智造近日宣布，拟以3.66亿元分别受让实控人汪建旗下深 圳华大三箭齐发科技有限责任公司（以下简称"三箭齐发"）、杭州华大序风科技有限公司（以下简 称"华大序风"）的100%股权。本次并非普通的资产腾挪，其核心在于将华大体系内代表生命科学研究 两大前沿方向的时空组学与纳米孔测序技术平台，正式纳入华大智造这一上市主体的版图中。在收购股 权的同时，华大智造将分别对三箭齐发、华大序风增资7000万元、6000万元。此外，华大智造还将向华 大序风提供7000万元的3年期借款用于偿债。 据了解，三箭齐发拟受让深圳华大生命科学研究院、北京华大生命科学研究院及华大智造等持有的时空 组学技术知识产权，交易价格为6534.15万元；华大序风拟受让深圳华大生命科学研究院、杭州华大生 命科学研究院等持有的纳米孔测序技术知识产权，交易价格为5617.44万元。上述股权转让完成后，华 大智造拟分别对三箭齐发、华大序风增资7000万元和6000万元，增资款用于其日常经营、主营业务扩 展、补充流动资金，以及分别向时空组学技术产权人、纳米孔测序技术产权人支付受让知识产权的对 价。 此外，收购完成后，华大 ...

证券代码：688114 证券简称：华大智造 公告编号：2026-005 深圳华大智造科技股份有限公司 关于公司收购资产及增资暨关联交易的公告 重要内容提示： 交易简要内容：深圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"或"受让方"）拟以现金 方式收购深圳华大科技企业管理有限公司（以下简称"华大科技"或"股权转让方"）所持有的受让时空组 学技术后的深圳华大三箭齐发科技有限责任公司（以下简称"三箭齐发"）的100%股权以及受让纳米孔 测序技术后的杭州华大序风科技有限公司（以下简称"华大序风"）的100%股权。本次交易以资产评估 机构出具的评估报告确认的标的公司评估值作为定价依据，经各方协商确认交易价格合计为36,570.00万 元，其中三箭齐发股权作价15,800.00万元，华大序风的股权作价20,770.00万元。 三箭齐发股权转让完成后，华大智造拟对三箭齐发增资7,000.00万元人民币，其中2,215.19万元人民币计 入其注册资本，4,784.81万元人民币计入其资本公积。三箭齐发保证，公司的前述增资款应全部用于其 日常经营、主营业务扩展、补充流动资金、向时空组学技术产权人支付受让知识产权的 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance company quality, stabilize the capital market, and support high-quality economic development [2] Group 1: Business Focus and Core Competitiveness - The company focuses on its main business, enhancing customer satisfaction and increasing R&D investment to improve market competitiveness and technological leadership [2] - The company has over ten years of R&D experience in molecular detection core technologies, making it one of the few domestic biotech firms with a complete business layout in this area [2] - The company has expanded its business into the screening and diagnosis of gastrointestinal diseases and respiratory infectious diseases, developing several innovative products and services [2][3] Group 2: Technological Advancements - The company has established a nanopore sequencing platform, which offers advantages such as ultra-long read lengths, compact and flexible equipment, and short sequencing times [3] - The nanopore sequencing technology has significant application potential in research, breeding, and pharmaceuticals [3] Group 3: Financial Performance - The company reported a total profit of -60.63 million yuan, a year-on-year decrease of 4.96%, and a net profit attributable to the parent company of -55.91 million yuan, down 11.70% year-on-year [3] Group 4: Marketing and Sales Strategy - The company has established 11 domestic sales regions and 2 international sales regions, with marketing offices in 12 cities, enhancing product promotion and market coverage [4] - A CRM system has been implemented to strengthen customer relationships and improve customer satisfaction and loyalty [5] Group 5: R&D and Innovation - The company has obtained multiple medical device registrations and patents, with ongoing R&D projects progressing steadily [6] - R&D expenses for the first half of 2025 amounted to 40.81 million yuan, a decrease of 11.32% year-on-year [5] Group 6: Operational Management - The company has improved operational efficiency through refined management practices across sales, R&D, production, and management [10] - Key performance indicators have been established to monitor production, material management, and customer support [12] Group 7: Corporate Governance and Investor Relations - The company emphasizes the importance of corporate governance and internal control systems to protect shareholder rights [13] - A stock incentive plan has been introduced to align the interests of shareholders and employees, involving 182 individuals [14] Group 8: Shareholder Returns - Due to negative net profits, the company does not meet the conditions for profit distribution but plans to use part of the raised funds for share repurchase to enhance investor confidence [15][16]

Core Insights - Gordon Sanghera has announced his resignation as CEO of Oxford Nanopore Technologies (ONT) after 21 years, prompting the board to initiate a search for a successor to lead the company into a new phase of growth and commercialization [1][2][4] - Under Sanghera's leadership, ONT pioneered nanopore sensing technology for sequencing, launching the MinION device in 2015, which has significantly impacted molecular analysis and served over 125 countries [3][4] - The company has faced legal challenges, including a recent lawsuit against BGI Group for patent infringement, which was later withdrawn, indicating potential shifts in the company's market strategy and leadership direction [4] Company Overview - ONT was co-founded by Gordon Sanghera, Hagan Bayley, and IP Group in 2005, with Sanghera serving as CEO since its inception [2] - The company has produced over 14,000 peer-reviewed publications, establishing itself as one of the fastest-growing sequencing companies in recent years [3] Leadership Transition - The board's search for a new leader is seen as a critical step for ONT to continue its success and adapt to industry changes [4] - Sanghera expressed confidence in the company's foundation for ongoing success, suggesting that the timing is right for a leadership change [4]